FADS1 (Fatty Acid Desaturase 1) encodes the delta-5 desaturase enzyme that converts short-chain omega-3 fatty acids¹¹ ALA (alpha-linolenic acid) is the plant-derived omega-3 found in flax, chia, and walnuts into the longer-chain EPA and DHA²² EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are the biologically active omega-3s essential for brain function and inflammation control that your brain and body actually use.

The Mechanism

The rs174547 variant sits in intron 9 of FADS1. The C allele (minor allele in most populations) is associated with lower delta-5 desaturase activity, meaning reduced ability to convert plant-derived ALA into the active EPA and DHA forms. Carriers of the C allele have higher levels of the omega-6 precursor linoleic acid and lower levels of arachidonic acid, EPA, and DHA.

Notably, the C allele frequency varies dramatically across populations — from just 6% in Africans to 46% in East Asians — reflecting different evolutionary pressures related to diet.

The Evidence

A landmark GWAS by Tanaka et al.³³ landmark GWAS by Tanaka et al.
Tanaka et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 in 1,075 participants identified the FADS1 locus as the strongest genetic determinant of plasma PUFA levels, explaining 18.6% of variance in arachidonic acid levels.

A meta-analysis by Chen et al.⁴⁴ meta-analysis by Chen et al.
Chen et al. Association between FADS1 rs174547 and levels of long-chain PUFA: a meta-analysis. Br J Nutr, 2021 confirmed that C allele carriers have significantly lower levels of long-chain PUFAs across multiple populations.

Why This Matters

Not everyone converts plant omega-3s efficiently. If you're a poor converter (CC genotype), eating flax seeds won't meaningfully raise your EPA/DHA levels. You need to get these directly from fish or supplements.

This is especially relevant for vegetarians and vegans⁵⁵ Algae-based EPA/DHA supplements offer a plant-based alternative to fish oil for poor converters who rely on plant sources for omega-3s.

Interactions

FADS1 function interacts with dietary patterns. If you also carry TCF7L2 risk alleles (rs7903146), getting adequate omega-3s from direct sources (fish, supplements) becomes even more important for cardiovascular protection.

Every bioactive peptide in your body starts life as an inactive precursor — a pro-protein that must be cleaved into its functional form. FURIN (also called PCSK3¹¹ PCSK3
proprotein convertase subtilisin/kexin type 3) is one of the most important enzymes responsible for these cuts. Its substrates include pro-BNP and pro-ANP²² pro-BNP and pro-ANP
heart-secreted hormones that lower blood pressure and reduce fluid retention, pro-renin³³ pro-renin
the inactive form of renin, the first enzyme in the blood-pressure- raising renin-angiotensin-aldosterone cascade, pro-endothelin-1, and pro-TGF-β. Essentially, FURIN sits at the top of multiple cardiovascular control systems simultaneously. The variant rs17514846, located in an intron of the FURIN gene on chromosome 15q26.1, alters how much of this enzyme is produced — with consequences for both coronary artery disease risk and blood pressure regulation.

The Mechanism

The rs17514846 variant operates through allele-specific epigenetic regulation⁴⁴ allele-specific epigenetic regulation
the same DNA sequence making different amounts of protein depending on chemical marks attached to it. The C allele contains a CpG dinucleotide — a sequence prone to methylation — directly at the variant position. When methylated, this CpG recruits the transcription repressor MeCP2⁵⁵ MeCP2
methyl-CpG-binding protein 2, a protein that binds methylated DNA and turns off nearby genes, which silences FURIN expression. The A allele, by contrast, destroys the CpG motif entirely — there is nothing to methylate, nothing to recruit MeCP2, and FURIN expression remains higher. Researchers confirmed this by treating C/C cells with a DNA methylation inhibitor, which increased FURIN expression to A/A levels.

In macrophages⁶⁶ macrophages
immune cells that accumulate in atherosclerotic plaques and are central to plaque development, higher FURIN from the A allele drives three pro-atherogenic behaviors: increased migration into arterial walls, faster proliferation, and reduced programmed cell death. The same phenomenon occurs in vascular endothelial cells⁷⁷ vascular endothelial cells
the cells lining artery walls that control what enters and exits the vessel wall: A-allele carriers show higher FURIN expression, elevated endothelin-1 (a potent vasoconstrictor), activated NF-κB signaling, more VCAM-1 and MCP-1, and greater monocyte adhesion and transendothelial migration — all hallmarks of early atherosclerosis.

The Evidence

The association between the chromosome 15q26.1 locus and coronary artery disease was first robustly established in GWAS meta-analyses through the CARDIoGRAMplusC4D consortium⁸⁸ CARDIoGRAMplusC4D consortium
a mega-consortium pooling CAD genetic data from hundreds of thousands of individuals. The A allele confers approximately 1.04–1.07-fold increased CAD risk⁹⁹ 1.04–1.07-fold increased CAD risk
a modest individual OR but important population-level effect given the high allele frequency. In the Bruneck Study, A-allele carriers showed higher circulating MCP-1 and greater carotid intima-media thickness¹⁰¹⁰ higher circulating MCP-1 and greater carotid intima-media thickness
two established intermediate biomarkers on the path to clinical heart disease.

The blood pressure dimension involves a related but partially independent mechanism. The ICBP/Global BPgen consortium GWAS in 200,000 Europeans¹¹¹¹ The ICBP/Global BPgen consortium GWAS in 200,000 Europeans
Ehret et al., Nature 2011 identified the FURIN-FES locus among those with genome-wide significant associations with systolic and diastolic blood pressure. The biology is consistent: when FURIN processes pro-BNP and pro-ANP into their active natriuretic forms, blood pressure falls. When FURIN processes pro-renin receptor (PRR) to regulate RAAS activity, blood pressure is modulated from the other direction. Higher FURIN from the A allele therefore activates intersecting vasodilatory and vasoconstrictive pathways simultaneously — net effect depends on tissue context and disease stage.

A Japanese cohort study found A-allele carriers had significantly lower triglycerides and higher HDL, suggesting metabolic syndrome protection in that population — an apparently paradoxical protective metabolic effect coexisting with elevated CAD risk through the vascular biology pathway.

Practical Actions

For A-allele carriers, the elevated atherosclerosis biology argues for aggressive management of all modifiable cardiovascular risk factors — not because of generic health advice, but because the genetic burden this variant adds is magnified by other risk factors. Specifically: measuring carotid intima-media thickness (CIMT) provides a direct readout of the subclinical atherosclerosis this variant promotes, and early detection allows intervention before clinical events occur. The inflammation axis (elevated MCP-1, VCAM-1, endothelin-1) makes high-sensitivity CRP a particularly informative biomarker for this genotype.

Carriers of two A alleles (AA genotype, approximately 23% globally) bear the greatest FURIN elevation and the highest cumulative risk. For them, cardiac screening conversations with a physician — including coronary calcium scoring when age-appropriate — are warranted earlier than population guidelines suggest.

Interactions

The rs17514846 locus includes several SNPs in high linkage disequilibrium — rs6224, rs11372849, and rs8039305 — that may contribute additional regulatory effects. The cis-eQTL variant rs4702¹²¹² rs4702
a FURIN 3'-UTR variant associated with both blood pressure and schizophrenia risk appears in partial LD with rs17514846 and affects FURIN expression through a distinct molecular mechanism, suggesting additive effects in individuals carrying both. There are no well-characterized interactions with other SNPs already in this database, but FURIN's broad substrate range means variants in RAAS genes (AGT rs699, AGTR1 rs5186) that affect the same blood pressure pathways could compound cardiovascular risk in a clinically meaningful way.

Most genetic risk variants for type 2 diabetes (T2D) are common, each nudging risk upward by a small amount. rs184660829 works differently: it is vanishingly rare — found in fewer than 1 in 2,500 people of European ancestry and essentially absent elsewhere — but carries one of the largest odds ratios for T2D yet identified in a genome-wide study. Carriers of the C allele face roughly 8 times the population risk of developing type 2 diabetes compared to the vast majority of people who carry two copies of the common T allele.

The Gene and Its Mechanism

DENND2C (DENN domain containing 2C¹¹ DENN domain containing 2C
a family of guanine nucleotide exchange factors (GEFs) that activate Rab GTPases) is a protein that controls vesicle trafficking — the cellular process by which membrane-bound packages of molecules are routed to their correct destinations. Rab GTPases are the molecular switches that direct this traffic, and DENND2C turns them on by catalyzing the exchange of GDP for GTP. Disruption of this switch-throwing activity has consequences for any tissue that depends on precise vesicle delivery, including the pancreatic beta cells that must release insulin granules on demand in response to rising blood glucose.

The rs184660829 variant sits 84 nucleotides upstream of a splice site in intron 11 of DENND2C (GRCh38: chr1:114,602,278, coding notation c.1668-84A>G on the minus strand). It is not in the protein-coding sequence and produces no amino acid change; instead, it may subtly alter splicing efficiency or local chromatin state in a tissue-specific way. The variant lies within a genomic region that, per islet epigenome maps used in the Mahajan 2018 fine-mapping study, shows regulatory chromatin marks in pancreatic islets — consistent with a gene-regulatory rather than structural mechanism.

The Evidence

Mahajan et al. (2018, Nature Genetics) fine-mapped T2D loci using high-density imputation in 898,130 European-descent individuals (71,124 cases, 824,006 controls) and integrated islet-specific epigenome data to prioritize functional signals.²² Mahajan et al. (2018, Nature Genetics) fine-mapped T2D loci using high-density imputation in 898,130 European-descent individuals (71,124 cases, 824,006 controls) and integrated islet-specific epigenome data to prioritize functional signals.
Mahajan A et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet. 2018 Nov;50(11):1505-1513. rs184660829-C emerged as one of the rare index variants (MAF <5%) with an estimated allelic odds ratio exceeding 2-fold — specifically OR=8.05 (95% CI 3.86–16.8, p=3×10⁻⁸), meeting genome-wide significance. The variant's risk allele frequency is approximately 2×10⁻⁴ globally, meaning the association was detected despite very few carriers, which underscores the strength of the biological signal.

Because the variant is intronic and its mechanism is not fully characterized, the evidence level is classified as moderate: the GWAS signal is genome-wide significant and the locus is biologically plausible, but functional validation in human islets and replication in non-European populations have not been published. The study was conducted exclusively in European-ancestry samples, and the C allele has not been observed at appreciable frequency in African, East Asian, South Asian, or Latino populations in gnomAD or ALFA population databases.

Practical Actions

Carriers of the C allele (TC genotype) should understand that their genetic background places them at substantially elevated T2D risk relative to the general population. The most evidence-backed strategies for individuals with high genetic T2D risk target fasting glucose monitoring and dietary carbohydrate quality — interventions with documented efficacy specifically in genetically at-risk individuals. Because the DENND2C locus likely affects beta cell vesicle function rather than insulin resistance in peripheral tissues, the primary vulnerability is in insulin secretion capacity, making monitoring of beta cell reserve (via fasting insulin and HOMA-B calculations) particularly informative.

Interactions

DENND2C rs184660829 is a recently discovered rare-variant signal and no published compound interactions with other T2D loci have been characterized. However, high-T2D-risk individuals carrying this allele who also carry common risk variants in TCF7L2 (rs7903146) or MTNR1B (rs10830963) may experience additive risk burden on a polygenic basis. These interactions are theoretical and have not been formally studied in the context of rs184660829.

MYBPC3¹¹ MYBPC3
myosin-binding protein C3, encoding the cardiac isoform of cMyBP-C — a 150 kDa structural protein in the thick filament C-zone of cardiomyocytes that regulates actomyosin cross-bridge cycling and myosin super-relaxation is the single most commonly mutated gene in familial hypertrophic cardiomyopathy (HCM), accounting for 40–50% of all genetically explained HCM cases. rs187830361 introduces a tryptophan-to-arginine substitution at codon 792 (p.Trp792Arg), sitting squarely in the C6 fibronectin type III²² fibronectin type III
a structural protein fold found in many extracellular matrix and sarcomeric proteins; in MYBPC3, FnIII domains form the modular "immunoglobulin-like" repeat scaffold that connects the protein to thick-filament myosin domain — one of three MYBPC3 sub-domains (C3, C6, C10) enriched for disease-causing missense mutations. ClinVar classifies the c.2374T>C (plus-strand A>G) change as Pathogenic/Likely pathogenic³³ Pathogenic/Likely pathogenic
VCV000036605; multiple submitters, no conflicts ★★; conditions include primary familial HCM, hypertrophic cardiomyopathy 4, and left ventricular noncompaction 10 across 11 independent submissions. The variant is absent or near-absent in gnomAD population databases, consistent with strong purifying selection against dominant cardiac disease alleles.

The Mechanism

Tryptophan 792 occupies a conserved hydrophobic core of the C6 FnIII domain. Replacing it with the bulkier, charged arginine residue disrupts the tight hydrophobic packing required for domain stability. Smelter et al. 2018⁴⁴ Smelter et al. 2018
Am J Physiol Heart Circ Physiol 314(6):H1179–H1191. Engineered cardiac tissue expressing W792R showed contractile kinetics nearly identical to cMyBP-C-deficient tissue, establishing functional haploinsufficiency as the pathogenic mechanism demonstrated that the W792R protein is expressed at substantially reduced levels despite normal mRNA abundance — the mutant protein folds abnormally and is degraded, leaving the cardiomyocyte functionally deficient in cMyBP-C from the mutant allele.

Unlike C10-domain missense variants (which fail to incorporate into myofilaments entirely), C6-domain W792R protein incorporates into the sarcomere at normal positions but disrupts the conformational dynamics that govern how cMyBP-C interacts with myosin heads and actin. Mertens et al. 2024⁵⁵ Mertens et al. 2024
J Mol Cell Cardiol 197:86-97. Homozygous W792R knock-in mice develop cardiac hypertrophy and fibrosis by postnatal day 10, lethal by day 21; heterozygotes show normal morphology, consistent with dominant-haploinsufficiency model showed in a mouse knock-in model that the mutation preferentially drives calcium-sensitizing interactions with actin rather than inhibitory interactions with myosin — the net result is increased basal contractility and the pathological remodeling characteristic of HCM.

Computational stability modeling⁶⁶ Computational stability modeling
STRUM algorithm; ΔΔG −1.28 kcal/mol for W792R; variants with ΔΔG ≤ −1.2 show HR 2.29 for adverse cardiac events independently predicts W792R as a destabilizing variant (ΔΔG −1.28 kcal/mol, just below the −1.2 kcal/mol clinical risk threshold), providing orthogonal support for pathogenicity beyond clinical case counts.

The Evidence

The W792R variant was established as pathogenic through a combination of functional characterization and clinical genetics. In the largest MYBPC3 cohort to date, Ho et al. 2021⁷⁷ Ho et al. 2021
Circ Genom Precis Med 14(1):e002929. SHaRe Registry; 1,316 patients with pathogenic MYBPC3 variants; nontruncating variants cluster in C3, C6, and C10 domains in 82% of cases; clinical outcomes equivalent between truncating and nontruncating carriers analyzed 1,316 MYBPC3 HCM patients from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) and found that C6-domain nontruncating variants — the class to which W792R belongs — produce equivalent adverse event rates to truncating variants. This refutes the prior assumption that missense variants are less severe than truncating mutations.

MYBPC3 pathogenic variants as a class show age-dependent, incomplete penetrance⁸⁸ age-dependent, incomplete penetrance
penetrance 50% by age 36, 75% by age 40, approaching 100% by age 55 in most founder cohorts; sex-dependent — males typically develop HCM 10-20 years earlier than females with the same variant. Heterozygous carriers who are phenotype-negative (no LVH on echocardiogram) remain at risk throughout life — particularly during periods of physiological stress such as pregnancy, competitive athletics, or rapid blood pressure elevation.

Sudden cardiac death (SCD) risk in MYBPC3 HCM is estimated at approximately 2-fold above background HCM risk, particularly in younger carriers with marked LVH (maximum wall thickness ≥30 mm), exercise-induced syncope, or non-sustained ventricular tachycardia on Holter monitoring.

Practical Actions

Carriers of the W792R variant require proactive cardiac surveillance regardless of current symptoms. The 2024 AHA/ACC HCM guideline recommends comprehensive echocardiographic evaluation at initial diagnosis, with periodic repeat imaging⁹⁹ periodic repeat imaging
gene-positive phenotype-negative relatives: annually in adolescence, every 3-5 years in adulthood; more frequent if subclinical markers present (diastolic dysfunction, myocardial crypts, elongated mitral leaflets) even before any structural change appears. Because LVH may not manifest until the 4th or 5th decade, a normal baseline echo is not reassuring for life — follow-up is mandatory.

Competitive high-intensity sport carries elevated SCD risk in HCM carriers. A sports cardiology or HCM specialist should provide activity guidance before any athletic competition. Pharmacotherapy (beta-blockers, disopyramide) can reduce outflow obstruction; mavacamten¹⁰¹⁰ mavacamten
a cardiac myosin ATPase inhibitor approved 2022; first disease-specific drug for HCM; reduces LV outflow tract gradient and improves symptoms in obstructive HCM is now guideline-supported for symptomatic obstructive HCM. ICD implantation is considered when SCD risk calculators indicate ≥4-6% 5-year risk.

Interactions

MYBPC3 W792R follows autosomal dominant inheritance — a single pathogenic copy is sufficient for disease. Compound heterozygosity (inheriting one truncating and one missense MYBPC3 variant, or two MYBPC3 variants from different parental alleles) can produce a more severe phenotype, up to pediatric lethal cardiomyopathy. If a relative is found to carry a different MYBPC3 pathogenic variant, the proband should be tested for that variant as well to exclude compound heterozygosity. Interactions with MYH7¹¹¹¹ MYH7
beta-myosin heavy chain; second most common HCM gene; MYBPC3 + MYH7 double heterozygotes have earlier onset and more severe HCM and other sarcomeric genes (TNNT2, TNNI3, TPM1) are documented — double-variant carriers have substantially earlier-onset, more penetrant disease.

First-degree relatives of confirmed W792R carriers have a 50% probability of inheriting this allele. Cascade genetic testing enables early surveillance and lifestyle modification before structural remodeling has begun — the window of maximum preventive opportunity.

The chromosome 6q25.1 region is one of the most replicated genetic risk zones for endometriosis. It harbors the estrogen receptor alpha gene (ESR1) and, just upstream, CCDC170 (Coiled-Coil Domain Containing 170) — a gene that encodes a Golgi-microtubule organizing protein. Variants across this region have been identified in multiple large GWAS studies spanning European, East Asian, and Taiwanese-Han populations. The rs1971256 C allele is one such signal: an intronic variant that sits within CCDC170 and contributes independently to endometriosis susceptibility beyond the well-studied ESR1 polymorphisms rs9340799 and rs2234693 already characterized on this platform.

The Mechanism

rs1971256 lies in intron 1 of CCDC170, at GRCh38 position chr6:151,494,876. The T allele is the GRCh38 reference; the C allele is the endometriosis risk allele identified in the GWAS Catalog (OR 1.09, p = 4×10⁻⁸). Because the variant is intronic, it does not change the CCDC170 protein sequence directly — instead, it likely acts as a regulatory or tagging variant influencing expression of CCDC170, neighboring ESR1, or both.

CCDC170 protein localizes to the Golgi apparatus, where it organizes Golgi-associated microtubule networks¹¹ Golgi-associated microtubule networks
the Golgi is a cellular sorting hub; its microtubule connections enable polarized protein trafficking and cell migration. Cancer-associated truncations of CCDC170 abolish Golgi localization and disrupt directional cell migration — a mechanism relevant to how ectopic endometrial cells survive outside the uterus and evade immune clearance. Co-regulation with ESR1 is central: fine-mapping studies of the 6q25.1 region in over 118,000 individuals found that risk variants here regulate both CCDC170 and ESR1 through distinct enhancer elements²² distinct enhancer elements
enhancers are non-coding DNA switches that control when and where genes are active, meaning a single variant can alter estrogen receptor expression, CCDC170 protein levels, or both simultaneously.

The net biological picture is of a locus where estrogen signaling efficiency and cellular polarity/migration are regulated in concert — two processes that together determine whether ectopic endometrial tissue can implant and proliferate outside the uterus.

The Evidence

The CCDC170 locus at 6q25.1 was first established as an endometriosis risk locus by a meta-analysis of 11 GWAS datasets totalling 17,045 cases and 191,596 controls³³ meta-analysis of 11 GWAS datasets totalling 17,045 cases and 191,596 controls
Sapkota et al. Nature Communications, 2017, which identified five novel endometriosis loci implicating sex steroid hormone pathways, including FN1, CCDC170, ESR1, SYNE1, and FSHB.

The most comprehensive evidence comes from a landmark meta-GWAS of 60,674 endometriosis cases and 701,926 controls across European and East Asian ancestry cohorts⁴⁴ meta-GWAS of 60,674 endometriosis cases and 701,926 controls across European and East Asian ancestry cohorts
Rahmioglu et al. Nature Genetics, 2023, which identified 42 genome-wide significant loci — the largest endometriosis genetic study to date. The 6q25.1 region (encompassing rs1971256) was among the replicated signals, with the C allele conferring OR ≈ 1.09 (p = 4×10⁻⁸). This is a modest per-allele effect typical of complex-trait GWAS: the C allele does not cause endometriosis, but each copy meaningfully shifts the population risk distribution.

Cross-ethnic replication strengthens confidence: a Taiwanese-Han GWAS of 2,794 cases and 27,940 controls⁵⁵ Taiwanese-Han GWAS of 2,794 cases and 27,940 controls
Sheu et al. Journal of Human Genetics, 2024 independently confirmed CCDC170 at 6q25.1 as a cross-population susceptibility locus alongside WNT4 and RMND1, suggesting the biological mechanism operates across ancestral backgrounds.

The risk allele C is notably more common in African populations (~69%) than in Europeans (~21%), which is informative for interpreting population-level risk distributions but does not change the per-allele effect estimate.

Practical Implications

This variant sits in the estrogen-signaling axis and provides additional evidence that a woman's risk for endometriosis is partially encoded in how her CCDC170 and ESR1 regulatory landscape is tuned. Clinically, the most important consequence is heightened vigilance: C allele carriers — especially CC homozygotes — benefit from earlier evaluation of pelvic pain symptoms rather than attributing them to normal dysmenorrhea.

For women with confirmed endometriosis who carry the C allele at this locus (and particularly those who also carry risk alleles at rs9340799 or rs2234693 in ESR1), the estrogen-pathway context informs medical management. Aromatase inhibitors such as letrozole and anastrozole⁶⁶ Aromatase inhibitors such as letrozole and anastrozole
aromatase converts androgens to estrogen in peripheral tissues including endometriotic implants; inhibiting it reduces local estrogen production are undergoing late-phase clinical trials for endometriosis pain, with promising results. Women with documented estrogen-pathway genetic risk may be better candidates for this class of therapy when first-line progestins fail.

Combined oral contraceptive (COC) selection also matters: progestin-dominant formulations (e.g., dienogest-containing pills, the levonorgestrel IUD) suppress ectopic implant growth more directly than estrogen-dominant formulations, which can in some cases stimulate lesion activity.

Interactions

rs9340799 (ESR1 XbaI) and rs2234693 (ESR1 PvuII): Both variants sit within the same 6q25.1 estrogen-signaling block as rs1971256. Fine-mapping studies indicate that rs1971256 is an independent signal — conditional analysis in GWAS data shows it retains significance after accounting for the classical ESR1 PvuII and XbaI variants. Women carrying risk alleles at multiple loci in this block (rs1971256-C + rs9340799-G + rs2234693-C) may face compounded estrogen-signaling dysregulation in endometrial tissue. A compound action is proposed below for women carrying risk alleles at both rs1971256 and rs9340799.

rs12700667 (near HOXA10): The WNT4-HOXA endometrial development axis represents a separate pathway; carrying risk alleles at both the estrogen-signaling (rs1971256) and developmental patterning (rs12700667) loci may additively increase endometriosis susceptibility, though formal interaction testing has not been published.

Your serum zinc level is not set only by diet. A common variant in the PPCDC gene¹¹ PPCDC gene
Phosphopantothenoylcysteine decarboxylase, an enzyme that catalyses the fifth step of coenzyme A biosynthesis from pantothenic acid (vitamin B5) influences how much zinc circulates in your blood, independently of how much you consume. Carriers of the C allele at rs2120019 tend to have lower serum zinc on average, an effect large enough to be genome-wide significant and consistently replicated as a genetic instrument in Mendelian randomization studies of zinc's role in cardiometabolic and infectious disease.

The Mechanism

PPCDC is not itself a zinc transporter. It encodes an enzyme in the coenzyme A (CoA) biosynthesis pathway²² coenzyme A (CoA) biosynthesis pathway
CoA is an essential cofactor in more than 100 enzymatic reactions including fatty acid synthesis, the citric acid cycle, and amino acid catabolism — converting 4'-phosphopantothenoylcysteine to 4'-phosphopantetheine. The intronic rs2120019 variant does not alter the PPCDC protein directly. Instead, the proposed mechanism is indirect: PPCDC variation may affect pantothenate metabolite pools, which in turn influence the expression or activity of downstream zinc homeostasis proteins, including zinc transporters expressed in the intestine and liver.

This mechanistic link remains incompletely characterized — the original GWAS authors acknowledged that "other genetic variation in the CoA synthesis pathway, specifically in PPCDC, could also lead to variation in Zn metabolism," while cautioning that this "cannot be taken further with current data." The association is robust at the epidemiological level (genome-wide significant, replicated across cohorts) even while the precise biochemical pathway is still under investigation.

The Evidence

The primary evidence comes from a genome-wide association study in 5,477 adults³³ genome-wide association study in 5,477 adults
Evans DM et al. Genome-wide association study identifies loci affecting blood copper, selenium and zinc. Hum Mol Genet, 2013 from the QIMR cohort (Australian twins and families) and the ALSPAC cohort (UK pregnant women). The rs2120019 C allele was associated with lower blood zinc at P = 1.55 × 10⁻¹⁸ (β = −0.287, SE = 0.033 standard deviations per C allele). This locus on chromosome 15 was one of only three genome-wide significant zinc signals identified, alongside chromosome 8 (near carbonic anhydrase genes) and chromosome X.

rs2120019 has subsequently been used as a standard genetic instrument in multiple Mendelian randomization studies. A 2018 two-sample MR study⁴⁴ 2018 two-sample MR study
Thun GA et al. Effects of copper and zinc on ischemic heart disease and myocardial infarction: a Mendelian randomization study. Am J Clin Nutr, 2018 found that the zinc instruments (including rs2120019) together explained ≥8% of variance in erythrocyte zinc and showed genetically instrumented higher zinc was associated with a modest increase in ischemic heart disease risk (OR 1.06; 95% CI 1.02–1.11). This counterintuitive finding — often interpreted as reflecting the U-shaped nature of zinc biology, where both deficiency and excess can be harmful — underscores that simply supplementing zinc indiscriminately is not appropriate even for lower-zinc genotypes.

In COVID-19 research, Moghaddam et al. 2021⁵⁵ Moghaddam et al. 2021
Association of Vitamin D, Zinc and Selenium Related Genetic Variants With COVID-19 Disease Severity. Front Nutr, 2021 included rs2120019 as the representative zinc genetic marker, while a larger MR analysis (Li et al. 2022⁶⁶ Li et al. 2022
Genetically Predicted Circulating Concentrations of Micronutrients and COVID-19 Susceptibility and Severity. Front Nutr, 2022) found limited evidence that genetically predicted zinc levels causally affect COVID-19 outcomes (OR 1.06 for hospitalization, 95% CI 0.81–1.39, p=0.66).

Practical Actions

The C allele at rs2120019 nudges serum zinc downward by roughly a quarter to a third of a standard deviation per copy. For a CC homozygote, this represents a meaningful shift in baseline zinc status that is worth accounting for in diet and monitoring — but does not require aggressive supplementation. Zinc is measured in serum or plasma; levels below 70 µg/dL in adults suggest inadequacy.

The best dietary sources of bioavailable zinc are shellfish (especially oysters), red meat, poultry, and legumes. Phytates in whole grains and legumes reduce zinc absorption, so soaking, sprouting, or fermenting these foods improves bioavailability. Supplemental zinc citrate and zinc gluconate are both absorbed at approximately 60%; zinc oxide has lower absorption at around 50%.

Avoid supplementing beyond 25 mg elemental zinc daily without confirmed deficiency — excess zinc can deplete copper, impair immune function, and, based on Mendelian randomization data, may be associated with elevated cardiovascular risk at the higher end of the zinc distribution.

Interactions

rs2120019 is one of three established zinc GWAS loci. The other two — rs1532423 (chromosome 8, near carbonic anhydrase genes) and rs11638477 (also associated with zinc) — are independent signals with separate mechanisms. Carrying the zinc-lowering allele at more than one of these loci would compound the downward shift in baseline zinc status, increasing the relevance of dietary zinc optimization and periodic monitoring.

Zinc bioavailability interacts with dietary copper: high-zinc supplementation competes with copper absorption, and vice versa. Users with both zinc-lowering and copper-altering variants should assess both minerals together rather than supplementing either in isolation.

Rheumatoid arthritis (RA) is driven by the chronic overactivation of NF-κB¹¹ NF-κB
Nuclear factor kappa-B — a master transcription factor that controls genes for TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines; it is normally held inactive in the cytoplasm by a family of inhibitor proteins called IκBs, the master inflammatory transcription factor. The gene NFKBIE encodes IκBε (IκB-epsilon)²² IκBε (IκB-epsilon)
Inhibitor of kappa-B epsilon — a member of the IκB family that binds primarily to RELA (p65) and REL NF-κB subunits, sequestering them in the cytoplasm and preventing inflammatory gene transcription; IκBε contains six closely spaced ankyrin repeats and operates more slowly than IκBα, acting as a late-phase dampener of NF-κB oscillations, one of the key brake proteins that normally keeps NF-κB restrained. The rs2233434 variant introduces a valine-to-alanine substitution at position 55 (p.Val55Ala in current transcript nomenclature; Val194Ala in older transcript annotations), which impairs the ability of IκBε to suppress NF-κB activity. In a landmark genome-wide association study, this G-allele variant emerged as one of the most significant non-HLA RA susceptibility loci identified to date.

The Mechanism

IκBε normally binds RELA and REL NF-κB subunits in the cytoplasm through its six ankyrin repeats, preventing them from entering the nucleus and activating inflammatory gene transcription. When cells are stimulated with pro-inflammatory signals (TNF-α, LPS, or antigen receptor engagement), IKK kinases phosphorylate IκBε, targeting it for proteasomal degradation and releasing NF-κB to translocate to the nucleus. Unlike the rapidly recycled IκBα, IκBε operates on a slower timescale and is responsible for dampening the late phase of NF-κB activation — functioning as an oscillation dampener that prevents sustained chronic inflammatory signaling.

The Val55Ala substitution is located in the ankyrin repeat domain of IκBε. Functional assays by Myouzen et al.³³ Functional assays by Myouzen et al.
Myouzen et al. 2012 — transfected HEK293 cells with risk (G-T) versus non-risk (A-C) haplotype constructs and measured NF-κB activity by luciferase reporter; the risk haplotype showed higher NF-κB transactivation and lower allelic transcript abundance, consistent with reduced inhibitory capacity demonstrated that the risk haplotype carrying the G allele of rs2233434 shows higher NF-κB activity compared to the non-risk haplotype, along with slightly lower transcript abundance — together suggesting that this variant both reduces the amount of IκBε protein and impairs the inhibitory function of whatever IκBε is produced. The net result is a leaky NF-κB brake: inflammatory stimuli activate NF-κB more easily, and the inflammatory signal lingers longer before being extinguished.

The Evidence

The primary discovery came from a large GWAS and two-stage replication in the Japanese population⁴⁴ large GWAS and two-stage replication in the Japanese population
Myouzen et al. 2012, PLoS Genetics — Japanese GWAS (stage 1) plus two independent replication cohorts; 7,907 RA cases and 35,362 controls total; rs2233434 reached genome-wide significance at OR=1.20, 95% CI 1.15–1.26, p=1.3×10⁻¹⁵. This established NFKBIE as the second-largest non-HLA RA risk locus at the time of discovery.

The association has since been replicated across multiple ancestries. Trans-ethnic meta-analysis⁵⁵ Trans-ethnic meta-analysis
Identified NFKBIE as having strong cross-population support: OR_EUR=1.25, OR_EAS=1.24, OR_AA=1.50, with a combined trans-ethnic p=1.57×10⁻¹⁹; the variant was identified as approximately 400 times more likely than the neighboring rs2233433 to be the pathogenic variant at this locus, with a posterior probability of pathogenicity of 0.482 confirmed that the effect is consistent in European (OR=1.25) and African American populations (OR=1.50), with the latter showing a notably larger effect size despite the G allele being rarer in African populations (~6%). These consistent trans-ethnic effects support a genuine biological role for this variant rather than a population-specific linkage artifact.

Beyond RA, a separate line of evidence connects this variant to drug response. Hashizume et al. 2016⁶⁶ Hashizume et al. 2016
Hashizume et al., Modern Rheumatology 2016 — overexpression of Val194Ala (rs2233434) mutant NFKBIE in human RA synovial fibroblasts (MH7A) showed reduced SLC19A1 mRNA compared to wild-type NFKBIE overexpression, particularly at methotrexate concentrations above 5 μM; methotrexate-polyglutamate accumulation was also reduced showed that the Val194Ala variant reduces expression of SLC19A1, the primary membrane transporter responsible for methotrexate uptake into cells. This creates a potential double vulnerability for G-allele carriers: higher baseline inflammatory signaling driving RA development, and potentially reduced efficacy of the first-line RA treatment methotrexate.

The risk allele frequency shows marked population stratification: G is found at approximately 18% in East Asian populations compared to only 4% in Europeans and 2% in South Asians. This higher frequency in East Asia may contribute to observed differences in RA prevalence and presentation across ancestries.

Practical Actions

For G-allele carriers, the most clinically relevant implication concerns awareness of RA risk markers and proactive monitoring. RA develops in predisposed individuals when genetic susceptibility combines with environmental triggers — smoking, periodontal disease, infections, and hormonal transitions. Early joint inflammation treated before significant cartilage erosion occurs preserves function dramatically better than late intervention.

The SLC19A1 connection also has practical implications: if G-allele carriers with RA are prescribed methotrexate and show inadequate response at standard doses, the NFKBIE variant may contribute to reduced drug uptake. Awareness of this pharmacogenomic dimension can guide earlier escalation to biological therapies when needed.

Interactions

NFKBIE functions within the canonical NF-κB pathway upstream of STAT4 (rs7574865). IκBε controls whether NF-κB enters the nucleus to produce IL-12 and IL-23 — the cytokines that STAT4 senses to drive Th1 polarization. Individuals carrying the NFKBIE G allele (more NF-κB activity, more IL-12/IL-23 production) together with the STAT4 T allele (higher IL-12/IL-23 sensitivity) may have amplified Th1 polarization relevant to both RA and other autoimmune conditions. This interaction has not been formally characterized for RA, but parallels the well-studied NFKBIE × STAT4 genetic architecture in SLE.

rs2233433 is a neighboring nsSNP in NFKBIE (Pro175Leu on older transcript numbering) that was studied in haplotype context with rs2233434 in the Myouzen et al. paper; the two form a risk haplotype (G-T) where both contribute to enhanced NF-κB activity. The rs41298997 IKBKE variant is in a different gene (IKKε kinase) but shares the NF-κB signaling axis; compound risk at both loci could amplify inflammatory signaling through both the inhibitor (NFKBIE) and kinase (IKBKE) arms of the pathway.

The thyroid-stimulating hormone receptor is the central target of Graves' disease autoimmunity. Stimulating autoantibodies (TRAbs) against TSHR permanently mimic TSH, overriding the pituitary's feedback control and driving unchecked thyroid hormone production. rs2268458 is an [intronic variant | A variant within a non-coding intron that can influence gene regulation and expression without altering the protein sequence] in the unusually large intron 1 of the TSHR gene — the same region that harbours the better-studied rs12101255 and rs179247 Graves' susceptibility variants. What sets rs2268458 apart within this locus is a notable absence: unlike some TSHR SNPs, this variant shows no statistically significant association with Graves' ophthalmopathy (GO), the orbital complication affecting 25–30% of Graves' patients, suggesting that not all intron 1 variants are regulatory equivalents.

The Mechanism

TSHR intron 1 contains regulatory elements that control tissue-restricted expression of the receptor, including in thymic epithelial cells — where autoreactive T cells are educated and eliminated. Reduced intrathymic TSHR expression, caused by risk variants in this region, means fewer TSHR-presenting cells are available for clonal deletion of autoreactive T cells, allowing TSHR-reactive T cells to escape into the periphery. A landmark 2014 PNAS study by Stefan et al.¹¹ Stefan et al.
Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity established this mechanism for adjacent rs12101255/rs12101261, identifying interferon-alpha-induced PLZF repressor binding as the epigenetic link between viral infection and thyroid autoimmunity.

The precise regulatory role of rs2268458 within this intron 1 region has not been separately characterised at the mechanistic level — Yin et al. 2008²² Yin et al. 2008
Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy noted that "direct functional analyses are now needed to help explain the mechanisms of this TSHR gene susceptibility." The variant's distinct phenotypic signature — Graves' disease susceptibility without ophthalmopathy association — implies it tags a regulatory effect at the TSHR locus that diverges from the orbital-disease pathway.

The finding that CC homozygotes face elevated relapse risk after antithyroid drug treatment (Eliana 2017) suggests the C allele may maintain a pro-autoimmune state that persists even after pharmacological thyroid function control — potentially reflecting impaired re-establishment of tolerance once the autoimmune response is triggered.

The Evidence

rs2268458 was identified as the most-associated TSHR SNP in a landmark study by Dechairo et al.³³ Dechairo et al.
Association of the TSHR gene with Graves' disease: the first disease-specific locus (2005), analysing 1,059 autoimmune thyroid disease cases and 971 controls. The haplotype containing rs2268458 reached P<1×10⁻⁶ (OR 1.7) in discovery and was independently replicated: GD P=2×10⁻⁶, OR 1.3, in 1,366 cases and 1,061 UK Caucasian controls. No association was found with autoimmune hypothyroidism, establishing this as a Graves'-specific signal.

Yin et al.⁴⁴ Yin et al.
Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy (2008) replicated the association in 200 female Caucasian GD patients versus 118 controls (OR 1.8, P=0.018 for C-containing genotype), and specifically examined 120 Graves' ophthalmopathy patients: no association with GO was found. The Xiong et al. meta-analysis (4,790 GD cases, 5,350 controls)⁵⁵ Xiong et al. meta-analysis (4,790 GD cases, 5,350 controls)
Genetic associations of the thyroid stimulating hormone receptor gene with Graves diseases and Graves ophthalmopathy (2016) confirmed that rs2268458 does not distinguish GO patients from GD-without-GO, reinforcing the variant-specific null ophthalmopathy finding.

A clinical study by Eliana et al.⁶⁶ Eliana et al.
Role of CTLA-4, TSHR and regulatory T-cells as risk factors for relapse in Graves disease (2017) extended rs2268458's clinical relevance: CC homozygotes showed significantly elevated relapse rates 12 months after antithyroid drug cessation (P=0.003) in 144 Indonesian patients, suggesting the CC genotype is not only a disease-onset marker but a treatment-response predictor.

Practical Actions

The C allele elevates Graves' disease susceptibility approximately 1.3–1.8-fold. Because rs2268458 does not predict ophthalmopathy independently, risk management for C allele carriers focuses on Graves' disease itself — early detection, thyroid function surveillance, and reducing modifiable autoimmune triggers.

CC homozygotes face the double burden of elevated disease onset risk and, if Graves' disease develops, elevated relapse risk after antithyroid drug treatment — making upfront awareness of treatment options (radioiodine ablation or thyroidectomy as definitive therapy) particularly relevant when discussing treatment strategy with an endocrinologist.

Selenium at 100–200 mcg/day has RCT evidence for reducing TRAb titres and autoimmune thyroid activity in Graves' patients; because the TSHR intron 1 risk variants appear to lower the immune-tolerance threshold for TSHR, selenium's immunomodulatory effect is a genotype-informed intervention for C allele carriers.

Interactions

rs2268458 maps to TSHR intron 1 alongside rs12101255 (the most-studied Graves' intron 1 SNP, with OR ~1.5–2.2 in meta-analyses) and rs179247. These three variants are in linkage disequilibrium and were co-studied in early TSHR haplotype work; whether rs2268458 contributes independently or purely as a tag for the rs12101255 haplotype block has not been resolved.

Syed et al. 2007⁷⁷ Syed et al. 2007
Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves' ophthalmopathy demonstrated statistical interaction between PTPN12 polymorphisms and the TSHR rs2268458 genotype in mild-to-moderate Graves' ophthalmopathy — an intriguing finding given that rs2268458 alone shows no GO association, suggesting the ophthalmopathy signal may emerge only in combination with PTPN12 variants rather than from rs2268458 in isolation.

Beyond the TSHR locus, independent Graves' susceptibility loci include PTPN22 rs2476601 (T-cell activation threshold), CTLA4 rs3087243 and rs231775 (T-cell checkpoint control), and HLA-DRB1 alleles (antigen presentation) — each acting through mechanisms distinct from the thymic TSHR expression pathway.

The TMPRSS6 gene produces matriptase-2¹¹ matriptase-2
A type II transmembrane serine protease expressed primarily in liver cells that acts as the body's main brake on hepcidin production, the enzyme that keeps hepcidin — the master iron-regulatory hormone — in check. Most genetic research on TMPRSS6 has focused on the Ala736Val variant (rs855791), which sits in the enzyme's catalytic domain. But rs228921, located roughly 2 kilobases upstream of the TMPRSS6 transcription start site, tags a second, independent signal at this locus. This upstream variant operates through a different mechanism: instead of altering the enzyme's activity, it likely affects how much matriptase-2 protein the liver produces. The result, however, is similar — lower matriptase-2 output means less hepcidin suppression, higher hepcidin, and reduced iron absorption from the gut.

The Mechanism

Matriptase-2 normally cleaves hemojuvelin²² hemojuvelin
A membrane-bound co-receptor that activates the BMP/SMAD signaling cascade, which drives hepcidin gene transcription in hepatocytes from the surface of liver cells. By removing this coreceptor, matriptase-2 blocks the BMP/SMAD pathway³³ BMP/SMAD pathway
Bone morphogenetic protein / son of mothers against decapentaplegic — a signaling cascade that upregulates hepcidin transcription and reduces hepcidin secretion. When matriptase-2 is produced at lower levels — as may occur with the G allele at rs228921 — this suppression is less effective. Hepcidin levels rise, ferroportin on gut enterocytes is internalized and degraded, and less dietary iron crosses the gut wall into the bloodstream.

rs228921 sits in low linkage disequilibrium with rs855791 (r² < 0.1 in European and Indian Asian populations), confirming that it is an independent genetic signal rather than a proxy for the Ala736Val variant. This means the two variants can be studied and act together as additive genetic risk⁴⁴ additive genetic risk
When two independent variants at the same locus both predispose to lower iron status, carrying both can compound the effect. An individual who is GG at rs228921 and also AA at rs855791 carries risk at two independent locations in the TMPRSS6 gene.

The Evidence

The landmark genome-wide association study by Chambers et al.⁵⁵ Chambers et al.
Chambers JC et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet, 2009 — conducted in 16,001 individuals of European and Indian Asian ancestry — identified rs228921 as independently associated with hemoglobin levels at genome-wide significance (combined P = 1.9 × 10⁻¹⁰). The variant clustered with rs228918 and rs228919 in a separate haplotype block from the primary rs855791/rs4820268 cluster, confirming its independent contribution to iron phenotype variation.

A systematic review⁶⁶ systematic review
Gichohi-Wainaina WN et al. Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators. Genes Nutr, 2015 documented comparable minor allele frequencies for rs228921 across Caucasian (MAF ~0.41) and Indian Asian (MAF ~0.48) populations, with this variant included among the eight TMPRSS6 SNPs showing inter-ethnic differences in association with iron status indicators.

A study in female Black South African populations found that the rs228918/rs228921 GG haplotype was associated with lower odds of elevated soluble transferrin receptor (sTfR > 8.3 mg/L; OR: 0.79, 95% CI: 0.63–0.98), illustrating how the biological effect of this upstream variant depends on haplotype context and may differ across ancestries — a reminder that iron-related genetic associations are influenced by population-specific haplotype backgrounds.

Practical Actions

For carriers of one or two G alleles, the implications parallel those of rs855791 but are additive: reduced TMPRSS6 activity → elevated hepcidin → lower iron absorption efficiency. The practical response focuses on the same strategies that improve iron uptake in the face of high hepcidin: pairing non-heme iron sources with vitamin C, choosing heme iron when possible, avoiding absorption inhibitors at iron-containing meals, and monitoring iron stores with periodic ferritin and transferrin saturation testing.

If a supplement is needed, iron bisglycinate⁷⁷ iron bisglycinate
A chelated amino acid form of iron that is absorbed partly through peptide transporters (PEPT1), bypassing the ferroportin bottleneck that hepcidin controls. Also labeled chelated iron or gentle iron is preferable to ferrous sulfate because its absorption is less dependent on ferroportin. Every-other-day dosing maximizes fractional absorption by allowing hepcidin to reset between doses.

The combined genetic picture matters: if you also carry the risk allele at rs855791 (or rs4820268), the two independent TMPRSS6 signals compound your predisposition toward lower iron absorption, making monitoring more important.

Interactions

rs228921 and rs855791 are in low LD (r² < 0.1) and represent independent signals at the TMPRSS6 locus — they can co-occur in the same individual and their effects are additive. Carrying both risk alleles compounds the predisposition to lower iron status. rs228918, rs228919, and rs575620 form a tight haplotype cluster with rs228921 and are likely in near-complete LD with each other.

TMPRSS6 variants also interact with HFE variants⁸⁸ HFE variants
HFE encodes a protein involved in hepcidin signaling. Loss-of-function variants C282Y (rs1800562) and H63D (rs1799945) reduce hepcidin and cause iron overload in homozygotes. See rs1800562. In individuals with HFE hemochromatosis variants, a hepcidin-reducing TMPRSS6 variant would amplify iron loading; conversely, in HFE carriers the higher hepcidin from TMPRSS6 risk alleles partially offsets the HFE-driven reduction. These opposing effects mean the clinical interpretation depends on what HFE variants are co-present.

The rs2546890 variant sits approximately 2,000 base pairs upstream of the IL12B gene¹¹ IL12B gene
located at chromosome 5q33.3, encodes the p40 subunit shared by interleukin-12 and interleukin-23, within a non-coding RNA locus designated LOC285626. IL-12 and IL-23 are cytokines produced by dendritic cells and macrophages that act as master switches for adaptive immune responses: IL-12 drives naive T cells toward the Th1 (IFN-γ-producing) lineage, while IL-23 sustains the Th17 (IL-17-producing) lineage. Both arms are implicated in autoimmune demyelination, psoriatic inflammation, and immune-mediated liver disease. The rs2546890 A allele has been associated in large genome-wide studies with elevated risk of multiple sclerosis, psoriasis, and primary biliary cholangitis — three immunologically distinct diseases unified by shared IL-12/IL-23 pathway dysregulation.

The Mechanism

rs2546890 is annotated as a non-coding transcript variant in the LOC285626 locus. Its position in the IL12B upstream regulatory region places it within a genomic neighborhood that contains multiple independently replicated autoimmune susceptibility signals. The IL12B locus at 5q33.3 harbors several GWAS-identified variants (including rs6887695 in the upstream region and rs3212227 in the 3′ UTR) that form a risk haplotype functionally linked to elevated p40 subunit expression in monocytes and dendritic cells. Carriers of the IL12B risk haplotype show increased IL12B mRNA and protein in antigen-presenting cells, leading to higher serum IL-12 and a Th1-polarized immune milieu²² increased IL12B mRNA and protein in antigen-presenting cells, leading to higher serum IL-12 and a Th1-polarized immune milieu
The p40 subunit is shared by both IL-12 and IL-23 heterodimers, so expression changes affect both cytokine outputs simultaneously. rs2546890 is in linkage disequilibrium with variants in this regulatory haplotype, likely tagging the same functional effect — enhanced transcription factor access to the IL12B promoter region during innate immune activation.

The Evidence

The association of rs2546890 with multiple sclerosis has been established across multiple large GWAS cohorts. The 2011 International MS Genetics Consortium (IMSGC) study³³ 2011 International MS Genetics Consortium (IMSGC) study
Sawcer et al., Nature 2011, PMID 21833088 analysed 9,772 MS cases and 16,849 controls of European ancestry across 23 research groups and identified the IL12B locus region among at least 29 novel susceptibility signals. The 2019 IMSGC genomic map⁴⁴ 2019 IMSGC genomic map
International MS Genetics Consortium, Science 2019, PMID 31604244 expanded this to 47,429 MS cases and 68,374 controls, confirming rs2546890 among 200 autosomal susceptibility variants, with an odds ratio of approximately 1.11 (p = 1×10⁻¹¹). An independent Italian cohort study Leone et al., PLOS ONE 2013, PMID 23785401⁵⁵ Leone et al., PLOS ONE 2013, PMID 23785401 found that rs2546890 near IL12B was the only non-HLA variant significantly associated with cerebrospinal fluid oligoclonal bands — a biomarker of CNS-compartmentalised inflammation — in 1,115 Italian MS patients (OR 1.45, 95% CI 1.09–1.92), validated by in silico replication in Scandinavian and Belgian cohorts.

For psoriasis, the IL12B locus is one of the most robustly replicated susceptibility signals. GWAS Catalog records for rs2546890 show associations at p = 1×10⁻²⁰ (OR 1.54, 95% CI 1.32–1.79) and p = 3×10⁻³⁵ (OR 1.39, 95% CI 1.32–1.47) across separate European cohorts. Pharmacogenomic studies link rs2546890 to biologic treatment response: Ovejero-Benito et al., Pharmacogenomics 2017, PMID 28470127⁶⁶ Ovejero-Benito et al., Pharmacogenomics 2017, PMID 28470127 found association with etanercept response at 6 months (n=68), and the same group Pharmacogenomics 2018, PMID 29192552⁷⁷ Pharmacogenomics 2018, PMID 29192552 found that rs2546890 was among five SNPs associated with PASI75 response to adalimumab or infliximab at 3 months (n=95). For primary biliary cholangitis, an international GWAS meta-analysis Cordell et al., 2015, PMID 26394269⁸⁸ Cordell et al., 2015, PMID 26394269 identified the locus at p = 5×10⁻¹² (beta = 0.133). The convergence of three immunologically distinct conditions on the same variant underscores its role as a broad immune-regulatory signal rather than a disease-specific variant.

Practical Actions

For individuals carrying one or two A alleles, the primary actionable implications are: (1) heightened monitoring for early signs of MS, psoriasis, and autoimmune liver disease; (2) awareness of the pharmacogenomic relevance to IL-12/IL-23 pathway-targeting biologics. Ustekinumab (Stelara) targets the p40 subunit encoded by IL12B — the protein whose expression is amplified by the risk haplotype this variant tags. Pharmacogenomic studies show that IL12B genotype influences ustekinumab response in psoriasis, making this result clinically relevant for biologic selection. Similarly, IL-12/IL-23 pathway-blocking biologics used in MS (natalizumab does not target this pathway directly, but newer agents such as ofatumumab act upstream in the B-cell/innate immune cascade implicated by this locus) are of increasing relevance.

Interactions

rs2546890 acts within the broader IL12B susceptibility haplotype that includes rs6887695 (upstream) and rs3212227 (3′ UTR). Individuals carrying risk alleles at rs2546890 alongside the IL12B 3′ UTR risk haplotype (rs3212227) likely have compounding effects on p40 expression. The IL23R rs11209026 (R381Q) loss-of-function variant provides strong protection against MS, psoriasis, IBD, and ankylosing spondylitis by reducing IL-23 receptor signaling downstream of the p40-containing IL-23 heterodimer. Carrying both the rs2546890 A risk allele (elevated IL12B expression) and the IL23R rs11209026 protective A allele creates a partial antagonistic interaction that would benefit from compound action analysis. The existing IL12B SNP rs12188300 in GeneOps operates on a partially overlapping locus; individuals carrying risk alleles at both rs12188300 and rs2546890 likely have additive effects on IL-12/IL-23 pathway amplification.